Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
Neurotech International (NTI) has flagged to its shareholders that the FDA hasn't granted its product NTI164 orphan drug status.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
GRE | Ann: AGM Date and Director Nominations | 04/10/24 | 0 | 222 | |||
|
|||||||
GRE | Ann: Julian Hanna Appointed Technical Adviser | 04/10/24 | 4 | 1.0K | |||
|
|||||||
GRE | Ann: Annual Report to shareholders | 30/09/24 | 0 | 266 | |||
|
|||||||
GRE | Ann: Appendix 4G - Corporate Governance Statement | 30/09/24 | 0 | 165 | |||
|
|||||||
GRE | GRE 2024 | 30/09/24 | 34 | 10K | |||
|
|||||||
GRE | CONTINUE / STEP DOWN / RETIRE | 25/09/24 | 0 | 232 | |||
|
|||||||
GRE | Ann: Whundo Copper Results Indicate Significant Growth | 19/09/24 | 6 | 3.3K | |||
|
|||||||
GRE | GRE AND ERW SURVEY ON X - TWITTER | 07/09/24 | 0 | 377 | |||
|
See All Discussions
Timeline
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
View More |